Therefore, although the infarction volume was similar in both EA groups, multiple EA application accumulates the enhanced effects on growth factors/receptors and neurotrophins/receptors expression and induces better sensorimotor improvements than single-time EA treatment. The gene discussed is BDNF; the disease is infarction.